Mutant and chimeric recobinant plasminogen activatorsproduction in eukaryotic cellsand preliminary characterization by Pierard, L. et al.
THE JOURNAL OF BIOLOGICAL CHEMISTRY 
0 1987 by The American Society for Biochemistry and Molecular Biology, Inc. 
Vol. 262, No. 24, Issue of August 25, pp. 11771-11778.1987 
Printed  in U.S.A. 
Mutant  and  Chimeric Recombinant Plasminogen  Activators 
PRODUCTION IN EUKARYOTIC CELLS AND PRELIMINARY CHARACTERIZATION* 
(Received for publication, December 23, 1986) 
Laurent  PierardS,  Paul Jacobs$, Dirk Gheyseng, Marc HoylaertsS, Bruno Andre$, 
Ljubica Topisirovic$, Alfred0 CravadorS, FranCoise de Forestat, Albert Herzog$, Desire CollenTl, 
Michel  De Wildet, and Alex  Bollen$ 
From the $Department of Applied Genetics, Uniuersiti Libre de Bruxelles, 24 rue de  I’Zndustrie, B-1400 NiveUes, Belgium, the 
§Molecular Genetics Department, Smith Kline RZT, 89 rue de I’Zmtitut, B-1330  Rixensart, Belgium, and the 
TCenter for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, Campus Gasthuisberg, 
49 Herestraat, B-3000 Leuven, Belgium 
Mutant urokinase-type plasminogen activator (u- 
PA) genes and  hybrid genes between tissue-type plas- 
minogen activator (t-PA) and u-PA have been designed 
to  direct  the  synthesis of new plasminogen activators 
and to  investigate  the  structure-function  relationship 
in  these molecules. The following classes of constructs 
were made starting from cDNA encoding human t-PA 
or u-PA: 1) u-PA mutants in which the Arg16’ and 
LyslSs were  substituted  with  threonine,  thus  prevent- 
ing cleavage by thrombin  and plasmin; 2) hybrid mol- 
ecules in which the NH2-terminal regions of t-PA 
(amino acid residues 1-67, 1-262, or 1-313) were 
fused with  the COOH-terminal region of u-PA (amino 
acids 136-411,  139-411, or 195-411, respectively); 
and 3) a hybrid molecule in which the second kringle 
of t-PA (amino acids 173-262) was  inserted between 
amino acids 130 and 139 of u-PA. In  all cases but one, 
the recombinant proteins, produced by transfected  eu- 
karyotic cells, were  efficiently  secreted  in  the  culture 
medium. The  translation  products  have b en tested for 
their ability  to  activate plasminogen after in situ bind- 
ing  to an insolubilized monoclonal antibody  directed 
against  urokinase. All recombinant enzymes were 
shown to be active, except those in which LyslaS of u- 
PA was  substituted  with  threonine. Recombination of 
structural regions  derived  from  t-PA, such as the  fin- 
ger,  the  kringle 2, or most of the A-chain sequences, 
with  the  protease part  or  the complete u-PA molecule 
did not impair  the  catalytic  activity of the  hybrid poly- 
peptides. This  observation  supports  the hypothesis that 
structural domains in t-PA and u-PA fold independ- 
ently  from one to  another. 
The fibrinolytic system plays a major role in  the removal 
of insoluble fibrin from the vascular bed. It is triggered by the 
conversion of an inactive proenzyme, plasminogen, into  the 
active enzyme, plasmin, which  will degrade fibrin clots into 
soluble components (1). 
Among several plasminogen activators, two immunologi- 
cally distinct enzymes, tissue-type plasminogen activator (t- 
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PA)’ and urokinase-type plasminogen activator  (u-PA), have 
been extensively studied (for a review,  see  Ref. 2). The first 
one, t-PA, found to be identical to blood plasminogen acti- 
vator (3), has been isolated from human uterus (4). The 
second enzyme, u-PA, has been identified in human urine  and 
kidney cells (5, 6). 
Both proteins are serine proteases of 70,000 and 54,000 
daltons, respectively, synthesized as single-chain polypeptides 
including a signal sequence involved in secretion (7-9). Single- 
chain plasminogen activators are processed by plasmin to 
form active enzymes composed of two disulfide-linked poly- 
peptides. t-PA is cleaved at  the Ar$78-Ile279 bond and single- 
chain u-PA (scu-PA), primarily, between Lyslm and Ile’” 
residues. Secondary cleavages in the u-PA molecule occur at 
the Arg’56-Phe’57 (with  thrombin) (10) and L y ~ ’ ~ ~ - L y s ’ ~ ~  
bonds, the  latter event producing the low molecular size form 
of the enzyme (33,000 daltons) which has similar properties 
as  the 54,000-dalton species (11). 
Although both enzymes activate plasminogen, t-PA  and  u- 
PA present different fibrinolytic properties. Indeed, plasmin- 
ogen activation by t-PA is highly fibrin-specific because the 
activator  binds to  the fibrin clot. Plasminogen then  binds to 
both  t-PA  and fibrin, thus forming a cyclic ternary complex 
with increased stability (12). Both single-chain and two-chain 
t-PA have very similar fibrinolytic efficacy; this implies that 
the conversion of single-chain to two-chain t-PA at  the  sur- 
face of the fibrin clot (13) has no physiological significance. 
On the contrary, two-chain u-PA displays little affinity for 
fibrin and activates free and fibrin-bound plasminogen 
equally well. Single-chain urokinase (scu-PA), which has been 
isolated recently by several groups (14-17), is a plasminogen 
activator with better fibrin specificity than u-PA (18-20). scu- 
PA thus displays intrinsic plasminogen activator properties 
(21,22). 
A comparison of the amino acid and nucleotide sequences 
of t-PA  and  u-PA reveals extensive homology between their 
B-chains (COOH-terminal regions) which carry the active 
site. The A-chains (NH2-terminal regions), however, differ in 
some significant aspects (7-9, 23, 24). t-PA contains two 
kringle domains, whereas u-PA  has only one. These kringle 
The abbreviations used are: t-PA, tissue-type plasminogen acti- 
vator; u-PA, urokinase-type plasminogen activator; scu-PA, single- 
chain u-PA ELISA, enzyme-linked immunosorbent assay; PBS, 
phosphate-buffered saline; SV40, simian virus 40; BGH, bovine 
growth hormone; bp, base pairs; kringle, triple loop disulfide-bonded 
structures occurring in t-PA (twice), u-PA (once), and plasminogen 
(five times); finger, amino-terminal region of t-PA, homologous to 
the finger-like domains in fibronectin; aa,  amino  acid(s). 
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domains are highly homologous to equivalent structures of 
plasminogen involved in  fibrin-binding (25, 26). In addition, 
the NH2-terminal region of t-PA contains  a finger-like do- 
main similar in structure to the fibrin-binding regions of 
fibronectin (27, 28). The high affinity of t-PA for fibrin has 
been attributed  to  the presence of both the finger and kringle 
domains in the enzyme (29, 30). Because plasminogen acti- 
vation by t-PA occurs with a low catalytic rate  constant  (k2 - 0.5 s-') (31), new plasminogen activators with both  a high 
fibrin specificity and a high turnover rate constant might 
constitute improved thrombolytic agents. Therefore, we have 
constructed, using recombinant DNA techniques, sequences 
coding for t-PA/scu-PA hybrids and for mutant scu-PA mol- 
ecules resistant to  the cleavage by plasmin. In  the present 
study, we found that  the recombinant proteins, produced by 
transfected eukaryotic cells, are efficiently secreted in the 
culture medium and, in most instances, display specific activ- 
ities for the activation of plasminogen comparable to  that of 
natural u-PA. 
EXPERIMENTAL PROCEDURES~ 
RESULTS 
Construction of Mutant u-PA and of Chimeric t-PA/u-PA 
Coding  Sequences-In an effort to improve thrombolytic se- 
lectivity and fibrin specificity of plasminogen activators, a 
family of vectors carrying sequences encoding new plasmino- 
gen activators have been created  through recombinant DNA 
technology. As outlined in the Miniprint Section, the  starting 
material for the new constructs is carried by three plasmids: 
pULBlOOO and pULB1135 carry  a preprourokinase cDNA (9) 
and pDSPl.lTPA25.BGH carries a t-PA precursor cDNA. 
The recombinant molecules derived from the manipulation of 
these DNAs share common features: they were all obtained 
as HindIII-Sac1 cassettes carrying a 5'-terminal sequence 
coding for a signal peptide and  a  3'-terminal sequence corre- 
sponding to  the whole or  partial B-chain of u-PA. In all cases, 
the u-PA catalytic site  has been maintained. The new con- 
structs, however, differed either in the  nature of the A-chain 
or in the sequence coding for the activation site of the proen- 
zymes. 
Full-length recombinant DNA  molecules  were obtained by 
subcloning various DNA fragments  into the Hind111 and Sac1 
sites of plasmid pULB1221 (42). When necessary, sequences 
joining DNA fragments of different origins were synthesized 
chemically and added to  the ligation mixtures. The conformity 
of the recombinant DNAs to  the expected sequences was then 
checked by DNA sequencing before proceeding to  the inser- 
tion of HindIII-Sac1 coding sequences into the eukaryotic 
transient expression vector pDSP1.1BGH (35), between the 
SV40 early promoter and the BGH polyadenylation signal 
(see Miniprint Section). Upon transfection in Chinese ham- 
ster R1610 or/and Cos I monkey cells, recombinant plasmin- 
ogen activators were produced and secreted in the culture 
medium. 
Characteristics of recombinant plasminogen activators  are 
shown in Table 2 and  the new enzymes schematically repre- 
sented  in Fig. 2. The products  can be classified in  three main 
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1, and Table 1) are presented in miniprint at the end of this paper. 
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groups. The first one consists of modified preprourokinase 
molecules (Table 2). Two of these enzymes, ppUK.410 and 
ppUK.410/366,  coded for by  pULB9122 and pULB9134, carry 
amino acid substitutions in the B-chain as compared to 
pULBlOOO and pULB1135. These modifications were intro- 
duced to assess their effect on enzymatic activity, in view  of 
the reported discrepancies between the deduced amino acid 
sequence of cloned preprourokinase (9)  and the sequence of 
the purified natural enzyme (23,24). Another set of constructs 
from the same group, Scupa n.c.410 and Scupa n.c.410/366 
(coded for by  pULB9129 and pULB9135), derives from the 
former molecules; additional amino acid substitutions have 
been introduced at  the physiological activation site in the 
proenzyme (Arg15'j and L Y S ' ~ ~  are respectively replaced by 
threonine). The purpose of these  constructions was to obtain 
prourokinase molecules with similar enzymatic properties as 
the  natural single-chain species (scu-PA) (18-20), but resist- 
ant to cleavage by plasmin. The last constructs belonging 
to the first group, pULB9139 and pULB9152 (coding for 
ppUK.(410/366/13l)del and Scupa n.c.(410/366/131)del), 
were designed to eliminate the secondary cleavage site of 
urokinase (L~s '~~-Lys '~ ' j )  and  to replace amino acid 131, tryp- 
tophan in pULBlOOO (9), by the cysteine residue found in  the 
natural  protein (23). This was achieved by deleting a  stretch 
of amino acids (132-147) and replacing it with a  shorter link 
(Ser-Thr) identical to  the one found in t-PA at comparable 
positions of the enzyme. The product ppUK.(410/366/131)del, 
coded for by pULB9139, consists thus of a deleted but activ- 
ableprourokinase, whereas Scupa n.c.(410/366/131)del,  coded 
for by  pULB9152, is deleted and non-activable. Finally, for 
comparison purposes, we constructed  a recombinant preprou- 
rokinase DNA (pULB9154) identical to that described by 
Heyneker et al. (8). 
The second group of constructions comprises four chimeric 
molecules. Taking  into  account  the hypothesis of exon shuf- 
fling as a mechanism for protein evolution (48), we tried to 
recombine cDNA fragments, derived from t-PA and u-PA, 
corresponding as precisely as possible to exons in the genes 
and to structural domains in the corresponding proteins. 
Fg.t-PA/UK.410 and Fg.t-PA/UK.410/366 (coded for by 
pULB9120 and pULB9124) result from the fusion of the 
finger domain of t-PA to the COOH-terminus of scu-PA. The 
two species are identical, except for the amino acid at position 
366 in urokinase (glycine in pULB9124 and cysteine in 
pULB9120). Both molecules were designed to explore the 
potential role of the t-PA finger domain (29) in fibrin binding 
when associated with scu-PA. Another molecule, tPPUK.410/ 
366, encoded by plasmidpULB9151, combines a larger portion 
of t-PA, the A-chain, to  the B-chain of u-PA; it is designed 
to confer to scu-PA the fibrin specificity of t-PA, which 
appears to be associated to  the A-chain moeity (49, 50). A 
similar product, tPKUK.410 (coded for by pULB9125), con- 
sists of the NH2-terminal part of t-PA containing the activa- 
tion site, up to amino acid 313 in the B-chain, fused to  the 
remaining COOH-terminal part of the B-chain of u-PA. 
The single representative of the  third group,  UK-K2.410/ 
366, coded for by plasmid pULB9137, is a nearly complete 
scu-PA polypeptide wherein the kringle 2 region of t-PA has 
been inserted between the single kringle domain and  the B- 
chain. It was designed to  test  the hypothesis that  the kringle 
2 region of t-PA behaves as an autonomous domain conferring 
fibrin binding ability to  the enzyme (30). 
Expression of Recombinant Plasminogen Activators in Cell 
Cultures-Eukaryotic cells transfected with the recombinant 
plasmids described above  were cultivated for 3-5 days in the 
presence of aprotinin to prevent conversion of the recombi- 
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TABLE I1 
General description of recombinant plasminogen activators 
Amino acid residue 
Plasmid  Product  denomination position" Description 
131  366 410 
pULBlOOO 
pULB1135 
pDSPl.lTPA25BGH 
pULB9122 
pULB9134 
pULB9154 
PPUK 
PPUK 
t-PA 
ppUK.410 
ppUK.410/366 
ppUK.410/366/131 
pULB9139 
pULB9129 
pULB9135 
pULB9152 
pULB9120 
pULB9124 
pULB9151 
pULB9125 
pULB9137 
Scupa n.c.410 
Scupa n.c.410/366 
Scupa n.c.(410/366/131)del 
Fg.t-PA/UK.410 
Fg.t-PA/UK.410/366 
tPPUK.410/366 
tPKUK.410 
UK-K2.410/366 
Val 
Val 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Ala 
Preprourokinase cDNA clone (9) 
Preprourokinase cDNA clone (9) 
t-PA cDNA clone 
ppUK where Val"' has been re- 
placed by  Ala 
ppUK.410 where Cysm has been 
replaced with Gly 
ppUK.410/366  where Trp131 has 
been replaced with Cys; iden- 
tical to preprourokinase previ- 
ously published (8, 23, 24) 
ppUK.410/366/131 where aa 
132-147 have been replaced by 
Ser-Thr 
ppUK.410 where aa 156 and 158 
have been replaced by Thr in 
order to produce an uncleava- 
ble ppUK 
Scupa n.c.410 where Cysm has 
been replaced by  Gly 
Scupa n.c. where aa 132 and 147 
have been replaced by Ser-Thr 
t-PA sequence from the ATG co- 
don to  aa 67  followed  by the 
sequence coding for aa 136 to 
the stop codon of prouroki- 
Fg.t-PANK.410 where aa corre- 
nase 
sponding to position 366  of 
prourokinase has been re- 
placed by  Gly 
t-PA sequence from the ATG co- 
don to  aa 262  followed  by the 
sequence coding for aa 139 to 
the stop codon of prouroki- 
nase 
t-PA sequence from the ATG co- 
don to aa 313  followed  by the 
sequence coding for aa 195 to 
the stop codon of prouroki- 
nase 
Sequence coding for kringle 2 of 
t-PA  (aa 173-262) inserted be- 
tween aa 130 and 139  of pre- 
Drourokinase 
Amino acid (aa) positions relative to preprourokinase sequence; aa 131 belongs to the A-chain and aa 366 and 
aa 410 to the B-chain. 
nant plasminogen activators secreted in  the medium.  Dosage 
of the recombinant polypeptides by ELISA using two mono- 
clonal antibodies, AAU2 and AAU6 (46), reveals that all 
recombinant plasmids, except pULB9125, direct the  transi- 
tory expression of urokinase-like material  (Table 3). Culture 
supernatants  and  extracts of cells transfected with pULB9125 
(tPKUK.410) were consistently negative when assayed with 
anti-urokinase or anti-t-PA  antibodies  (data  not shown). 
Plasminogen Activation by Immobilized Recombinant Acti- 
vators-The assay for plasminogen activation consisted of a 
two-step procedure. First,  standard urokinase or cell culture 
supernatants were incubated with matrix-bound monoclonal 
antibody AAU2. Specific complexes were then exposed to 
plasminogen and to a plasmin-specific chromogenic substrate, 
D-Ile-Pro-Arg-p-nitroanilide. Any plasmin resulting from the 
activation of plasminogen will thus react with the  substrate 
and release the paranitroaniline chromophor which can be 
monitored at 405 nm. In  all cases, typical sigmoidal curves 
were observed when plotting absorbance as  a function of time 
( t )  (data  not shown). As previously described by Drapier et al. 
(47),  plotting of AdO5 as  a function of squared time (e) enables 
us to linearize the assay as long as  initial conditions are valid 
(see Miniprint  Section) (Fig. 3). The slope of these straight 
lines is almost proportional to  the total u-PA concentration 
present in the experimental standard incubation mixtures at 
the moment of enzyme immobilization onto matrix-bound 
antibody (Fig. 3, inset). From this relationship it is concluded 
that, within the experimental range tested (0-8 IU/ml), the 
amount of immobilized enzyme is proportional to  the u-PA 
concentration in the upstanding solution. The dose-depend- 
ent plasminogen activation thus enables us to evaluate the 
enzymatic activity present in initial incubation mixtures. 
Compared to  the curves obtained with control u-PA (Fig. 
3), those for all recombinant plasminogen activators  and for 
purified natural  scu-PA appeared biphasic. As shown for three 
different dilutions of the recombinant ppUK.410/366 (pULB- 
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FIG. 2. Schematic representation of the A-chain structural 
domains in recombinant plasminogen activators. Open and solid 
lines correspond to sequences originating from scu-PA and t-PA, 
respectively.  The  different  recombinant  plasminogen  activators are 
indicated by the following letters: A, t-PA; B, u-PA, ppUK.410, 
ppUK/410/366, or ppUK/410/366/131; C, ppUK.(410/366/13l)de1; 
D, Scupa n.c.410 or Scupa  n.c.410/366; E, Scupa  n.c.(410/366/13l)del; 
F, Fg.t-PA/UK.410  or  Fg.t-PA/UK.410/366; G, tPPUK.410/366; H, 
tPKUK.410; I ,  UK-K2.410/366. Arrows point  to  cleavage  sites. Rel- 
evant  disulfide  bridges, in the A-chain and  between the A- and  B- 
chains, are shown. For simplification purposes, B-chains are only 
partially represented. Numbers refer to structural domains of A- 
chains: I ,  finger domain of t-PA; 2, epidermal  growth  factor domain 
of t-PA; 3, kringle 1 of t-PA; 4, kringle 2 domain of t-PA; 5, epidermal 
growth  factor  domain of u-PA; 6, kringle  domain of u-PA. 
9134), the linear phase was preceeded by an exponential lag 
phase (Fig. 4A). Pretreatment of immobilized recombinant 
plasminogen activators with plasmin (or with trypsin)  and 
careful elimination of the converting enzyme completely abol- 
ished this  initial lag phase in subsequent plasminogen acti- 
vation experiments (Fig. 4B). Slopes measured in  both exper- 
imental conditions were identical, considering the steep part 
of the curves only. The data thus indicate that  the initial 
phases, as observed in Fig. 4A, correspond to  the activation 
of the immobilized recombinant activators which, under the 
experimental conditions, are harvested essentially as single- 
chain molecules. This was confirmed by the fact that  the same 
lag phase was observed with standard one-chain urokinase 
purified from Calu-3 cell line (data not shown). Therefore, 
the enzymatic activity present in cell culture supernatants 
was determined by comparing the slopes of the linear part of 
the curves obtained for recombinant enzymes (Fig. 4A) to  the 
standard u-PA system (Fig. 3). The enzyme activities are 
presented in Table  3 for all recombinant plasminogen acti- 
vators tested; activities ranged from 0 to 4.5 IU/ml of culture 
supernatant. Apparent specific activities of the recombinant 
plasminogen activators were obtained by the ratio of measured 
activities to  the amount of antigen (assuming that they display 
similar affinities for the monoclonal antibodies AAU2 and 
AAU6 as  the  standard 54,000-dalton u-PA). As seen in Table 
3, values range from 35,000 and 100,000 IU per mg  of 54,000- 
dalton  activator, except for non-activable scu-PA molecules. 
From these data,  it can be concluded that two-chain recom- 
binant enzymes activate plasminogen with catalytic efficien- 
cies comparable to  that of u-PA and, thus, that they have 
maintained a correct three-dimensional active site. On the 
other  hand, no or only very  weak activity has been found in 
the supernatants of respectively R1610 and Cos I cells al- 
though they expressed efficiently the non-activable scu-PA 
molecules. As expected, the modification of the activation site 
resulted in a single-chain product which cannot be trans- 
formed into  the two-chain active species in the presence of 
plasminogen and chromogenic substrate or by plasmin (data 
not shown). Whether non-convertible scu-PA-like and  natu- 
ral scu-PA will  be able to activate plasminogen directly in a 
freely diffusing system remains to be determined. 
DISCUSSION 
Thrombolytic agents lacking fibrin specificity, such as u- 
PA or streptokinase, induce thrombolysis but  in association 
with generalized plasminogen activation and fibrinogen 
breakdown. t-PA induces thrombolysis with a high  degree of 
clot selectivity due to a markedly higher rate of plasminogen 
activation at  the surface of the fibrin clot, as compared to 
rates observed in the absence of fibrin (12). Efficient and 
fibrin-selective thrombolysis has also been obtained with scu- 
PA, the single-chain precursor of u-PA (22). The mechanism 
of this selectivity is not fully understood but  appears  distinct 
from that of t-PA. 
One way to design improved thrombolytic agents would 
consist of the combination, in a single molecule, of two 
essential characteristics: high fibrin-mediated plasminogen 
activation and low fibrin-independent plasminogen activa- 
tion. Such agents would be expected to display, in uiuo, a 
fibrinolysis/fibrinogenolysis ratio at least equal or superior to 
that of t-PA or scu-PA. 
In the present study, three main groups of plasminogen 
activators have been produced; first, we constructed scu-PA- 
like  molecules (Scupa n.c.410 and Scupa n.c.410/366) wherein 
conversion to two-chain urokinase was prevented by substi- 
tuting two amino acids involved in the cleavage of the  natural 
scu-PA molecule. This approach finds its rationale in the fact 
that  the conversion of scu-PA into u-PA, in uiuo, is not a 
prerequisite for thrombolysis, but leads to a loss in clot 
selectivity. 
In  a second approach, we recombined several domains de- 
rived from the A-chain of t-PA with u-PA (in  part or in toto). 
Fg.t-PA/UK.410 and Fg.t-PA/UK.410/366 consist of the low 
molecular weight scu-PA carrying on its NH2 terminus the 
finger domain of t-PA; tPPUK.410/366 contains the A-chain 
of t-PA fused to the low molecular weight scu-PA, and 
tPKUK.410 is similar to tPPUK.410/366 but contains the 
cleavage site of t-PA. We hypothesized that some of these 
molecules might not only induce clot selectivity for plasmin- 
ogen activation, via the mechanism of scu-PA, but also en- 
hance fibrin specificity by binding to  the clot via their t-PA 
structures. Another hybrid product, UK-K2.410/366, carries 
the  putative fibrin binding domain of t-PA (kringle 2) inserted 
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Plasmid 
TABLE I11 
Expression levels and activity determinations of recombinant plasminogen activators 
Cell type 
R1610 cos I 
Gene product 
ELISA” supernatant 
Activity in 
Ib 
pULB9122 
pULB9134 
pULB9139 
pULB9120 
pULB9124 
pULB9151 
pULB9125 
pULB9137 
IIb 
pULB9134 
pULB9129 
pULB9135 
pULB9151 
pULB9137 
IIIb 
pULB9122 
pULB9154 
pULB9135 
~ULB9152 
ppUK.410 
ppUK.410/366 
ppUK.(410/366/13l)del 
Fg.t-PA/UK.410 
Fg.t-PA/UK.410/366 
tPPUK.410/366 
tPKUK.410 
UK-K2.410/366 
ppUK.410/366 
Scupa n.c.410 
Scupa n.c.410/366 
tPPUK.410/366 
UK-K2.410/366 
ppUK.410 
ppUK.410/366/131 
Scupa n.c.410/366 
ScuDa n.c.(410/366/131)del 
3.6 
3 
3.2 
12 
11.4 
0 
1.9 
1.1 
74.3 
18 
29 
6.6 
13.8 
7.5 
7.5 
9 
3.8 
IU/ml 
0.23 
0.2 
0.22 
0.43 
0.49 
0.21 
0 
0.08 
2.64 
0 
0 
4.44 
0.43 
0.48 
0.36 
0 
0 
Appar- 
ent Activity in 
specific supernatant 
activity” 
IU/W wlml  IU/ml 
62,400 
66,000 
68,900 
35,300 
43,000 
109,900 
0 
69,000 
35,500  48 
0 
2.28 
40 
0 
0.12 
96 0.57 
66,300  21.5  1.34 
31,250  7.3  0.38 
63,500 8.4 0.62 
48.000 6.9  0.52 
Appar- 
ent 
activity” 
specific 
IU/mg 
47,000 
2,900 
5,900 
62,000 
52,200 
73,700 
75,000 
0 6.5 0.02 3,100 
0 4 0.01 2,500 
. . I .  
Concentrations and  apparent specific activities are given in 54,000-dalton urokinase equivalents. 
I, 11, and I11 refer to  three independent  transfection experiments. 
FIG. 3. Kinetic analysis of plasminogen activation by puri- 
fied u-PA. Formation of paranitroanilide was recorded at 405 nm. 
The system contains purified u-PA linked to  the monoclonal antibody 
AAU2, plasminogen (1 PM) and the plasmin-specific chromogenic 
substrate o-Ile-Pro-Arg-p-nitroanilide (0.5 mM). Data were plotted 
versus squared time. Slopes of the linear phases represent the accel- 
eration of paranitroanilide formation. Four concentrations of purified 
u-PA were assayed 0, 7.9 IU/ml; 0, 2.5 IU/ml; B, 0.79 IU/ml; A, 
0.25 IU/ml. Inset, acceleration of pNA formation plotted versus u- 
PA activities. The curve can be used to evaluate the activity present 
in cell culture supernatants assayed on microtiter plates. 
into the nearly complete scu-PA molecule; this form is ex- 
pected  to yield a potent  urokinase-like plasminogen activator 
showing  high fibrin  affinity if, indeed, the kringle  2  behaves 
as  an  autonomous  domain. 
All recombinant plasminogen activators, except  tPKUK.410, 
were efficiently  produced in cell cultures.  In  addition, specific 
activities of recombinant two-chain u-PA and of chimeric 
polypeptides were comparable  to  that of natural  u-PA,  indi- 
cating  that  the  catalytic  site  carried by the  urokinase moiety 
of the molecules has been maintained  and  is fully functional 
for  plasminogen activation. 
The recombinant uncleavable scu-PA molecules (Scupa 
n.c.410 and  Scupa n.c.410/366), derived from  transfected 
R1610 cells, did  not show any  activity  in  our  assay system. 
However, the supernatants derived from transfected Cos I 
cells exhibited a slightly higher level of activity than the 
control.  This  is  apparently  due  to  the  secretion by the cells of 
an endogenous plasminogen activator.  Indeed,  pretreatment 
of Cos I cell supernatant with plasmin confirmed this  hypoth- 
esis (data not shown). We showed also that plasmin was 
unable to convert uncleavable scu-PA derived from trans- 
fected R1610 cells into  an amidolytically active species. This 
observation  supports  the conclusion that  Scupa n.c. proteins 
are effectively stable  one-chain molecules. Whether  the  ab- 
sence of the  activation  site in the  Scupa n.c. molecule has  any 
decisive influence on  its biological in  vitro and in vivo activi- 
ties will be investigated  in more detail once the  recombinant 
product  is  obtained  in large amounts  and purified. 
The  scu-PA molecule encoded by the cDNA described in 
Jacobs et al. (9) differs at  three  positions  from  the  amino acid 
sequence of the  natural  protein  (23,24)  and  from  the deduced 
sequence  derived from  an  independently  isolated cDNA  clone 
(8). We showed that  none of these differences had a  significant 
effect on  the  production levels and  on  the plasminogen acti- 
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FIG. 4. Kinetic analysis of plasminogen activation by  recombinant ppUK.410/366 secreted in  culture 
medium of transfected Cos I cells. In A ,  procedure was as for Fig. 3. Three dilutions of the cell culture 
supernatant were tested 0, undiluted supernatant; 0, 3-fold dilution; W, 10-fold dilution. Slopes of linear phases 
were used to evaluate the activity of the  supernatants by comparison to  the  standard curve shown in the inset of 
Fig.  3. In E, procedure and dilutions of cell culture supernatant were as for A except that ppUK.410/366 linked to 
the monoclonal antibody AAU2 was converted to its two-chain form, prior to  the assay, by exposure to plasmin as 
described under  “Experimental Procedures.” The  data show that  the lag phases observed in A are due to the 
conversion of one-chain ppUK.410/366 to  its two-chain form. 
vation capability. In  addition, deleting the cleavage site  re- 
sponsible for conversion of 54,000-dalton u-PA to 33,000- 
dalton u-PA ( L ~ s ’ ~ ~ - L y s ’ ~ )  was equally without effect. 
A number of hypotheses might be tested once these  mutant 
and chimeric plasminogen activators have been produced in 
efficient host/vector systems, extensively purified, and  char- 
acterized. A first step in this direction has been already 
achieved for two of our constructs, pULB9122 (ppUK.410) 
and pULB9120 (Fg.t-PA/UK.410), and  the  data  are pr sented 
in the accompanying paper (51). 
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EXPERIMENTAL  PROCEDURES 
uareria1s: 
Restriction endonucleases. T4 DNA p~lymerase.  T4  DNA ligase. Eocherichia 
coli DNA polymerase I (Klenou fragment) and T4 polynucleotide kinase were 
Biolsbo. Apiorlnln was from Sigma. f e t a l  c a l f  s e r u m  from Flow laboraforiee 
purchased  from  Boehrlnger-Mannhelm  Biochemxcals.  Amersham or  New England 
and D-Val-Leu-Lys-p-nifroanilide (S2251) f rom Kablvltrum. Human ~ l a s n i n o ~ e n  
was purified 8s dercrlbed (32). One and  two-chaln  urokinase were prepared fGom 
human l u n g  adenocarcinoma  line  Calu-I  (ATCC,  HTB-551 as deecrlbed by Stump  et 
al.(l7). Thelr acfivlties w e r e  determined using the reference standard 
uraklnase o f  Calblochem-Behring Carp. There acfivlfles were 7 0 , 0 0 0  IUImg and 
79,100 I U I m g  respectluely f o r  one-chain  and  two-chain urokinase. 
been described earller. Plasmid pDSPl.lTPAZ5BGH,provided by D r .  Reff. is a 
Plasmids p U L B  I000 (9). pULB  1118 (9), pJRDl84 ( 3 3 1  and  pJRD158 ( 3 4 1  have 
pDSPl.1BGH-like  plasmid  wherein a f-PA cDNA has  been  inserted.  Plasmid 
cloned ~n rhla plasmid a r e  flanked by the S Y 4 0  early promoter end the BGH 
pDSP1.lBGH (38) is e transient expression v e c t o r  for eukaryotic cells. Genes 
polyadenylation site. A11  recombinant genes described  in  this p a p e r  have  been 
introduced i n  pDSP1.lBGH a s  Hind 111-Sac  I casseLte9 (fzg. I ) .  The  procedures 
e l .  ( 3 6 1 .  Oligodeoxynucleotides were synthesized on a Applied Blosysfem 
for DNA  preparsrion  and resrrlction analysis were as published by Hanlafis e t  
Synthesizer  model  380  A via the  solid-phase  phosphorarnldite  method 8s 
previously described (37,38,39). Llgaflon e n d  bacterial &ransformarion of  
eccording t o  Uenlatio e t   a 1  (16). The methods of Maxam s o h  Gllberf ( 4 0 )  and 
Escherichia coli K12 strain MH 294 (end*, thr .hsr-. hrm ) were performed 
Senger e t  8 1 .  (41) were  used for DNA S e q u e n c e  analysis. 
pULB  9122 
This  recombinant  plesmd  codes  for  preprourokinase. If has been 
constructed a s  fallows: B 1440 bp 8x1 I - a 1  I DNA fragment v a s  derived from 
plasmid  pULB 1000. If encompasses  the  urokinase  =DNA molecule coding f o r  a s  16 
in  the slgnal sequence t o  the  stop  codon  and  lncludes  in its 3 '  terminus.  the 
poly C extension and 124 bp of pBRl22 sequences. This fragment was treated 
with T4 DNA polymerase (I61 and llgated on its 5 '  end Lo a 21 bp Hind III- 
Table 1 1  t m  COOSLIULT the sequence corresponding t o  the ATG  initiating coda; 
and the urokinase signal peptide UP t o  a 8  -16. The molecule coding f o r  
preprourokinese. ppUK. v a s  then ligated (16) TO the intermediate E. C O I L  
x88 further manipulated firstly to remove exceeding I' p o l y  C and pBR322 
plasmid.  pULB 1 2 2 1  (42). cut with  and u. The  resulting  plasmid 
sequences, and secondly t o  substitute the codon for V a l  410 present in pULB 
1000 or  pULB 1135 by a codon  specifying  Alanine.  This was done by replacing a 
211 bp BemH I-Sac I DNA fragment by a 21 bp double-stranded synthetic DNA 
adaptor (adaptor 2.Table 1 )  coding f o r  amino acld 398 t o  the stop codon 
followed by B protruding end. A 1309 bp H i n d  111-Sac I c a s s e t t e  coding 
for ppUK.410 was excised from the resulting recombinant  plasmld  pULB  9117  and 
PULB  9122. 
inserted i n f o  the Y e C f o ~  pDSPl.1BGH. t o  produce  the f r n a l  recomblnanf plasmid 
(blunt ended site1 double-stranded synthetic DNA adaptor (adaptor I 
PULB  9129 
This  plasmid carries the sequence c o d l n g  f o r  preprauroklnase i n  which  the 
activation sxte (Arg 156-Phe 157-Lyr 158) is replaced b v  Thr 156-Phe 157-Thr 
recovered.  This  fragment carries o n  i t s  I' end,  the ATG iniriafng  codon.  the 
158.  Srartlng from plasmid pULB 9117. B 1175 b p  M - B a r n B  I fragment was 
sequence coding from aa-19 t o  aa149 o f  preprourak~naoe and. on 1 f 8  5 '  end.  the 
sequence coding for a a  198 t o  the stop codon. those two  regions being 
separated by the sequence8  o f  pULB 1221 present in the  plaenid  pULB  9117. On 
the  other  hand. a 292 bp EcoR I-Xho I1 f r a g m e n t  coding f o r  a e  163 to a *  260 o f  
preprourokinase was derived f r o m  PULB  9117.  A  thlrd fragment , B 4 1 4  bp 
- piece f r o m  PULB  9117.  encoding aa 260 t o  a a  398 o f  the 
adaptor coding f o r  as 149 to oa  161 including the two  amino acid substit- 
preprourokinase. was purlfled. At last, a double-stranded 4 1  b p  Bsl  I-EcoR I 
described above  (adaptor 4. Table I 1  w a s  synfheaired.  The f o u r  fragments were 
lrgared to g e n e r a t e  the recornblnanf plasmid pULB 9128. The Hind 111-Sac I 
c a s s e t t e  cadlng f o r  S c u p a  n.c.410 was recovered from pULB 9128 8 8  e 1309 bp 
fragment  and  xnrraduced into pDSP1.1BGH. resulting i n  pULB  9129. 
IULB  9135 
PULE  9135. I* ldentxcal f a  pULB  9129 e x c e p t  that  the  codon for Cysteine 
366 has been  replaced by a codon f a r  G l y c i n e .  The  procedure  used f a  construct 
PULE 9135 is Identical t o  the o n e  described for pULB 9114. The recombinant 
Biasmld pULB 9131 Codlnn f o r  unacrlvable oreorouroklnese ( F r n n a  n.r 1101366) 
: -sac  I 
i G E  
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Table 1: Sequences of the synthetic DNA adaDtor8. 
ADAPTOR 1 :  
:: AG CTT ACC ATG AGA GCC CTG C 3 Met Arg Ala Leu L(eu! 
A TGG TAC  TCT CGG GAC G 5' 
Hind I l l  B g l  I blunt 
ADAPTOR 2 :  
iT G ATC CGC ACT CAC ACC A A G  G A A  GAG AAT GGC CTG GCC CTC TGA G A G  CT 3 '  r)p Ile Arg Ser His Thr L y s  G l u   G l u  Asn Gly Leu Ala Leu STOP 
9 '  GCG TCA GTG TGG TTC CTT CTC TTA CCG GAC CGG G A G  ACT C 5 '  
BamHI sac I 
ADAPTOR 3 :  
5 '  AC AAG CCC TCG AGT CCT CCA G A A   G A A  TTA AAA TTT CAG TGT GG 3 
(T)yr Lys Pro Ser Ser P r o  Pro G l u  Glu Leu L y s  Phe Gln Cys Gl(Y? 
3 '  TG TTC GGG AGC TCA G G A  GGT CTT CTT AAT TTT A A A  GTC ACA CC 5 '  
Rsa I B a l  I 
ADAPTOR 4 :  
(Gl)y Gln Lya Thr Leu Arg P r o  Thr Phe Thr Ile Ile Gly Gly G(lu) 
5' C CIA AAG ACT CTG AGG CCC ACC TTT ACC ATT ATT GGG GGA G 
3 '  G GTT TTC TGA GAC TCC GGG TGG AAA TGG TAA TAA CCC CCT CTT AA :: 
B e l  I Eco R I  
ADAPTOR 5 :  
( G ) 1 y  Pro Le" V a l  cy9 ser Le" GI" Gly 
5 '  G A  CCC CTC GTC TGT TCC CTC CAA GGC 
3 '  66 GAG CAG ACA AGG G A G  GTT CCG G 2:  
Ava I1 Fnu4H I 
ADAPTOR 6 :  
;:e)r Pro Cys Trp Va(l) 
3 '  G GGA ACG ACC CAC TAG :: C  CCT TGC TGG GT 
B c l  I 
ADAPTOR 7 :  
(P)m Leu V a l  Gln Glu Cys Her V a l  His Asp Cys Ser Glu Gl(7) 
5 '  CG CTA GTA CAA GAG TGC ATG GTC CAT GAC TGC TCT GAG  GG 
9 '  C GAT CAT GTT CTC ACG TAC CAG GTA CTG ACG A G A  CTC CCA GCT :: 
Fnu4H I S a l  I 
ADAPTOR 8: 
(T)yr Cys Asp V a l  Pro Ser Cye Ser Ser Pro Pro Glu G l u  Leu Lys Phe Gln Cys Gl(y) 
5 '  AC TGT GAC GTC CCC AGC TGC TCG AGT CCT CCC GAG GAA CTT A A G  TTT CAG TGT GG 3 '  
3 '  TG ACA CTG CAG GGG TCG ACG AGC TCA G G A  G G G  CTC CTT GAA TTC A A A  GTC ACA CC 5 '  
RSB I BAL I 
ADAPTOR 9: 
( P ) r o  Leu V a l  Gln Glu Cye Her V a l  His Asp Cys Ser Thr Cys Gl(y) 
5' CA CTA GTC CAA G A G  TGC ATG GTG CAT GAC TGC TCC ACC TGT G G  3 '  
3 '  T GAT CAG GTT CTC ACG TIC CAC GTA CTG ACG AGG TGG ACA CC 5' 
Ral I 
ADAPTOR 108: 
( P ) r o  Leu  V a l  Gln G l u  Cys Met V a l  His Asp Cys Ala ASP 
5' CG CTT  GTC CAA GAG TGC ATG GTG CAT GAC TGC GCA GAT 
3 '  C G A A  CAG GTT CTC ACG TAC CAC GTA CTG ACG CGT CTA CCT TTT  TTC GGG :: 
P""4H I 
ADAPTOR lob: 
5: GGA A A A  AAG CCC TCC TCT CCT CCA G A A  G A A  TTA AAA TTT CAG TGT G G  3 
G l y  Lye Lya Pro Ser  Ser Pro Pro Glu G l u  L e u  L y s  Phe Gln Cys Gl(y! 
3 AGG A G A  G G A  GGT CTT CTT AAT TTT A A A  GTC ACA CC 5 '  
B a l  I 
Double-stranded DNA adaptors were  synthesized chemically ae single-stranded 
oligonucleotides  and  hybridized prior t o  ligation (36). 
pULR 9139 
pULB 9124 
pULB 9124 IS ldentlcal t o  pULB 9110 except t h a t  t h e  codon c o r r e s p o n d l n y  
to a a  3 6 6  of p r e p r o u r o k i n a s e  has been replaced by a codon for g l y c l n e .  We 
ligated B 452 bp Hlnd 111-Bal I fragment  purifled  from pULB Yll5, encoding t h e  
r e g i o n  f r o m  t h e  ATG i n i f ~ a t l n g  codon t o  aa 6 7  of t-PA and aa 136 L o  1 4 9  o f  
encampasslng the l a r g e  Hlnd 111-Sac I f r a g m e n t  of pDSPL.1RGH and t h e  
preprourokinase to B 6975 bp Hind 111- Bal I fragment  from pULB 9 1 3 4  
sequence coding f o r  a8 1 4 9  t o  the s t o p  codon  of Dreprouroklnase. 
DULB 9137 
pULR 9137 carries the gene coding for 8 "  hybrld m o l e c u l e  where  the amino 
acld s e q u e n c e  corresponding to the k r l n g l e  2 of f-PA L E  inserted b e t w e e n  the 
to 255 o f  L-PA and for 8 8  1 3 9  L o  1 4 9  o f  preprauroklnase were exclsed. T h e s e  
173 to 1 7 4  of L - P A  and 8 297 by Dde I-Bal I p i e c e  from p B A Z  r o d l n ~  for a a  174 
t w o  fragments were llgsfed to a 3673 b p  Nca I-Bel I DNA fragment  derlved f r o m  
ATG i n l t l a t l n n  codon, for the s l g n a l  pepf~de and  far 1 t o  66 o f  
pULB 9119. This last p i e c e  o f  DNA carries o n  1 f 3  3 '  end the sequences  for the 
krlngle 2 o f  t-PA and the p r o t e a s e  m o e x t y  of u r o k i n ~ ~ e .  A second 822 b p  _ _ _ ~  Hlnd 111-EcoR I UNA f r a g m e n t ,  coding  for the  ATG codon. t h e  5 1 ~ n a l  s e q u e n c e  
and e a  1 to 204  o f  f-PA , was obtained from pDSPl.ITPA25BGH. T h e  last 
f r a g m e n t .  1 s  a 6975 bp Hind 111-Bal I stretch from pULB 9134. This fragment 
carries t h e  c o d ~ n g  sequence from a s  I 4 9  t o  the stop signal of preprourokinase 
and a l l  t h e  sequences o t  DDSPI.LBGH f r o m  the to UI. The t h r e e  
f r a g m e n t s  w e r e  llgafed t o  obraln pULB 9151 which c a r r l e ~  a 1823 b p  -11- 
i ~ e f f e  coding f o r  tPPllK.4101366. C B I  
by l l g a t l n g  5 DNA fragments  dlrecfly to t h e  6180 bp Hlnd Ill-Sac I fragment o f  
195 t o  t h e  stop codon) o f  preprouroklnase. The c o n s f r u r f ~ o n  has b e e n  achleved 
pDSPL.1BGH. The 5 f r a g m e n t s  a r e :  
~ a 8 2 2  bp Hlnd 111-EcaR I f r a g m e n t  from pDSPl.ITPA258GH. If c o n r d l n s  t h e  
~ e q u e n c e s  coding f o r  t h e  l n l r i a t i n g  codon, t h e  s i g n a l  pepf~de and an  1 t o  204 
